Published in
American Society of Hematology, Blood, 21(131), p. 2345-2356
DOI: 10.1182/blood-2017-10-809210
Links
Tools
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma
Journal article published in 2018 by
Elena Battistello,
Natalya Katanayeva,
Elie Dheilly,
Daniele Tavernari,
Maria C. Donaldson,
Luca Bonsignore,
Margot Thome,
Amanda L. Christie,
Mark A. Murakami,
Olivier Michielin,
Giovanni Ciriello,
Vincent Zoete,
Elisa Oricchio 
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Inhibition of BTK in patients who are resistant to ibrutinib changes signaling tumor dependencies and promotes MYC upregulation. Multitarget inhibition of LYN, FYN, and BLK is therapeutically effective in patients with DLBCL independent of their molecular subtypes.